Friday, December 29, 2023 12:23:33 PM
The timing is hard to dissect, as many PR's were only on the old Sohm website, and now they can't be accessed as they've been removed from the new website. Brainwise was technically a little before Aguilar and Rushing were appointed as advisors, might have been a little limited in what they could "say" or contribute...though as you're pointing out they were "advisors." Also as you point out, now they may have more teeth as Officers/Employees/Management/Leadership.
They still seem to be interested in a Brainwise "product" as the most recent quarterly includes an "Omega 3 Oral syrup." (?)
However, whatever happened to Gabapentin? What did Aguilar say about it?
Gabapentin isn't in the Quarterly as a "saleable product." Have they abandoned Gabapentin?
TIA. hL shmn
They still seem to be interested in a Brainwise "product" as the most recent quarterly includes an "Omega 3 Oral syrup." (?)
However, whatever happened to Gabapentin? What did Aguilar say about it?
Gabapentin isn't in the Quarterly as a "saleable product." Have they abandoned Gabapentin?
TIA. hL shmn
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
